Exicure and Bluejay sign hepatitis treatment development deal
Under the deal terms, Bluejay will have the sole licence to Exicure’s patents relevant to hepatitis. Bluejay made an initial payment to Exicure following the deal execution. In
Ferring Pharmaceuticals and SK pharmteco have entered into an agreement to increase commercial manufacturing capacity for Ferring’s ADSTILADRIN (nadofaragene firadenovec-vncg), ensuring a long-term supply of the non-replicating adenoviral vector-based gene therapy.
The transaction, which was executed through Zuellig Pharma’s wholly-owned subsidiary Zanovex, encompasses several Association of Southeast Asian Nations (ASEAN) territories. These markets include Cambodia, Brunei, Laos, Indonesia, Malaysia,
The treatment is intended for usage in adults with priorly untreated la/mUC. This development marks a significant step towards potentially offering an alternative to the current standard platinum-containing